Skip to main content

GI/Liver

PRES - Posterior reversible encephalopathy syndrome. Review of US hosp records finds 3125 cases.

Dr. John Cush RheumNow ( View Tweet)

Jul 02, 2020

Liver Abnormalities in Psoriatic Arthritis

Jul 01, 2020

A new report in the Journal of Rheumatology shows that liver abnormalities are common in psoriatic arthritis (PsA) and may be associated with obesity, more severe disease and select therapies.



An analysis of a prospective PsA cohort study included 1061 patients. Of these, over one-

Read Article
Rituximab (RTX)-associated autoimmune disease flare is rare and only seen in 7/185 pts (3.4%); all w/ type II mixed cryoglobulinemia vasculitis.

Dr. John Cush RheumNow ( View Tweet)

Jul 01, 2020
If you treat #SLE patients, Do you get a renal biopsy before starting therapy for Lupus nephritis?

Dr. John Cush RheumNow ( View Tweet)

Jun 27, 2020
Metanalysis of 8 studies and >130,000 patients shows that IBD (Crohns & UC) have a significantly higher risk of developing #RA (RR = 2.59; 95% CI: 1.93–3.48). https://t.co/ipYRZ6DQPQ

Dr. John Cush RheumNow ( View Tweet)

Jun 24, 2020
NEJM case report of PD-1 inhibitor induced immune related colitis successfully treated with tofacitinib 10 mg bid for 30 days - patient improved after 5 days of TOFA. https://t.co/skfU6TKnlK

Dr. John Cush RheumNow ( View Tweet)

Jun 22, 2020
RheumNow Podcast is Up! New FDA approvals for secuminumab, canakinumab, risk of GI perforations, tocilizumab in COVID, Weaning DMARDs/Biologics and Blacks with AS.

Dr. John Cush RheumNow ( View Tweet)

Jun 20, 2020

RheumNow Podcast – Enough Already with Weaning (6.19.20)

Jun 19, 2020

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.

Read Article

Year of the Wolf: Lupus at EULAR2020

Jun 10, 2020

For a disease that has been recognized since the days of Hippocrates, we are finally making some progress towards understanding systemic lupus erythematosus (SLE) and how to tame the wolf.  Listed below are the top 5 studies and their summaries presented at the recent EULAR e-Congress

Read Article

Serum calprotectin: a better biomarker in ANCA-associated vasculitis?

Jun 10, 2020

Flares in ANCA-associated vasculitis are difficult to predict, but serum calprotectin may help predict relapse and renal failure, according to data presented at the EULAR 2020 virtual meeting this week.

Read Article
Study of the French registries for TCZ, RTX, ABA, compared the risk of GI perforations (GIP). GIP risk was higher with TCZ (vs RTX,ABA) but was largely due to TCZ increasing the risk of diverticulitis.
Dr. John Cush RheumNow ( View Tweet)
Jun 06, 2020
#EULAR2020 Plenary Abstr#OP0016 Brilliant study showed how gut microbiota dysbiosis may trigger RA in high risk people (+CCP w/o Sx) using fecal transplantation in a mouse model to trigger collagen induced arthritis @rheumnow Healthy vs. preclin RA vs.
Jun 05, 2020
Interesting abstract #ABO113, out of Germany found that H. Pylori ab p66-UreB, p29-UreA, and p54-flagelin are more prominent in PsA/PsO pts. Another suggested potential link to the gut microbiome and dz? Hopefully, more data to come.

Dr. Rachel Tate uptoTate ( View Tweet)

Jun 05, 2020

TNR Grand Rounds - Update on Biosimilars

Jun 03, 2020

This week's Tuesday Nite Rheumatology featured Dr Jonathan Kay (U Mass) who gave an update on Biosimilars and took questions the subject. The program was moderated by Dr. Jack Cush.

Read Article

RheumNow Podcast - Rheumatic Patients with COVID (5.29.20)

May 29, 2020

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

Read Article

RheumNow Podcast - COVID Kids and Men (5.15.20)

May 15, 2020

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

Read Article

RheumNow Podcast – The Beat Goes On (5.8.20)

May 07, 2020

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.

Read Article

German Society of Rheumatology COVID Pandemic Recommendations

Apr 30, 2020

The Annals of Rheumatic Disease has published the preliminary recommendations of the German Society of Rheumatology for the management of Inflammatory rheumatic diseases patients during the SARS-CoV-2/Covid-19 pandemic.

These preliminary recommendations are based on an expert consensus from 17

Read Article

RheumNow Podcast – In Times of Trouble (4.24.20)

Apr 24, 2020

Dr Jack Cush reviews the news, journal reports, twitter feed and COVID developments from the past week on RheumNow.com

Read Article

COVID-19 Systemic Involvement

Apr 15, 2020

The presentations of the COVID-19 infection have been clearly chronicled with the worrisome onset of sore throat, dry cough, loss of smell and taste with fevers, myalgias, fatigue and the worrisome progression of pulmonary involvement in a minority.  Lab findings may include a leukocytosis,

Read Article

RheumNow Podcast – The Beginning of Something Else (4.10.20)

Apr 10, 2020

Dr Jack Cush reviews the news and journal reports from the past week on RheumNow.com

Read Article

TNR - Grand Rounds: Safety of Biologics & New Agents

Apr 08, 2020

On Tuesday, April 7th, RheumNow hosted its first Tuesday Nite Rheumatology webinar - kicking off a two-month series of Rheumatology Grand Rounds lectures.  The first session featured Jack Cush, MD (UT Southwestern) who lectured on "The Safety of Biologics and Newer Agents".

This 30

Read Article

EMA Final Recommendations on VTE Risk with Tofacitinib

Mar 10, 2020

On 14 November 2019 the European Medicines Agency (EMA) concluded that Xeljanz (tofacitinib) could increase the risk of blood clots in the lungs and in deep veins in patients who are already at high risk.  These recommendations have been formally published and are intended for EU nations

Read Article

Adverse Effects of Low-Dose Methotrexate from the CIRT Trial

Feb 18, 2020

Low-dose methotrexate (LD-MTX) was studied in high risk cardiac patients in the cardiac intervention trial (CIRT), but was prematurely ended for not showing a change in cardiovascular event rates. Nonetheless this trial studied the safety and adverse event rates of LD-MTX and those results are

Read Article

Biosimilars for Rheum Disease: Failure to Launch

Jan 21, 2020

The availability of biologic biosimilars has thus far had negligible impact on prescribing practices in the United States, in stark contrast to what has been observed in some European countries, researchers reported.

Analysis of claims data from a large commercial health plan found that

Read Article
×